CGP-7930 was the first positive allosteric modulator of GABAB receptors described in literature.

[1][2][3][4] CGP7930 is also a GABAA receptor positive allosteric modulator and a blocker of Potassium channels.

[5] CGP7930 was developed in Novartis and has been used extensively for scientific research.

It has anxiolytic effects in animal studies,[6][7] and has a synergistic effect with GABAB agonists such as baclofen and GHB,[8][9] as well as reducing self-administration of alcoholic drinks and cocaine.

[10][11]